39 related articles for article (PubMed ID: 14695406)
1. BCMA- and CST6-specific CAR T cells lyse multiple myeloma cells and suppress murine osteolytic lesions.
Sun F; Cheng Y; Chen JR; Wanchai V; Mery DE; Xu H; Gai D; Al Hadidi S; Schinke C; Thanendrarajan S; Zangari M; van Rhee F; Tricot G; Shaughnessy JD; Zhan F
J Clin Invest; 2024 Jan; 134(1):. PubMed ID: 37883186
[TBL] [Abstract][Full Text] [Related]
2. Medication-related osteonecrosis of the jaw (MRONJ) and eNOS Polymorphisms in multiple myeloma patients: a single center experience.
Taş Ozyurtseven B; Serin I; Nursal AF; Pehlivan S; Pehlivan M
BMC Oral Health; 2021 May; 21(1):272. PubMed ID: 34006261
[TBL] [Abstract][Full Text] [Related]
3. Hypophosphatemic osteomalacia: an unusual clinical presentation of multiple myeloma.
Reyskens M; Sleurs K; Verresen L; Janssen M; van den Bergh J; Geusens P
Osteoporos Int; 2015 Jul; 26(7):2039-42. PubMed ID: 25906239
[TBL] [Abstract][Full Text] [Related]
4. Mesenchymal stem cells inhibit multiple myeloma cells via the Fas/Fas ligand pathway.
Atsuta I; Liu S; Miura Y; Akiyama K; Chen C; An Y; Shi S; Chen FM
Stem Cell Res Ther; 2013; 4(5):111. PubMed ID: 24025590
[TBL] [Abstract][Full Text] [Related]
5. Multiple myeloma and paget disease with abnormal skull lesions and intracranial hypertension.
Caravita T; Siniscalchi A; Montinaro E; Bove R; Zaccagnini M; De Pascalis D; Morocutti A; Brusa L; Arciprete F; Cupini M; Perrotti A; Palma E; Fratoni S; De Simone R; Iani C; de Fabritiis P
Mediterr J Hematol Infect Dis; 2012; 4(1):e2012068. PubMed ID: 23205256
[TBL] [Abstract][Full Text] [Related]
6. Myeloma cells inhibit osteogenic differentiation of mesenchymal stem cells and kill osteoblasts via TRAIL-induced apoptosis.
Fu J; Wang P; Zhang X; Ju S; Li J; Li B; Yu S; Zhang J; Zhang X
Arch Med Sci; 2010 Aug; 6(4):496-504. PubMed ID: 22371791
[TBL] [Abstract][Full Text] [Related]
7. Diseases of Wnt signaling.
Johnson ML; Rajamannan N
Rev Endocr Metab Disord; 2006 Jun; 7(1-2):41-9. PubMed ID: 16944325
[TBL] [Abstract][Full Text] [Related]
8. Tumors of the osseous spine.
Sundaresan N; Boriani S; Rothman A; Holtzman R
J Neurooncol; 2004; 69(1-3):273-90. PubMed ID: 15527096
[TBL] [Abstract][Full Text] [Related]
9. Myeloma cells and bone marrow osteoblast interactions: role in the development of osteolytic lesions in multiple myeloma.
Giuliani N; Rizzoli V
Leuk Lymphoma; 2007 Dec; 48(12):2323-9. PubMed ID: 18067006
[TBL] [Abstract][Full Text] [Related]
10. [SDF-1/CXCR4 and multiple myeloma osteolytic bone lesions--review].
Bao L; Huang XJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Apr; 16(2):442-6. PubMed ID: 18426683
[TBL] [Abstract][Full Text] [Related]
11. A new insight into the formation of osteolytic lesions in multiple myeloma.
Glass DA; Patel MS; Karsenty G
N Engl J Med; 2003 Dec; 349(26):2479-80. PubMed ID: 14695406
[No Abstract] [Full Text] [Related]
12. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma.
Tian E; Zhan F; Walker R; Rasmussen E; Ma Y; Barlogie B; Shaughnessy JD
N Engl J Med; 2003 Dec; 349(26):2483-94. PubMed ID: 14695408
[TBL] [Abstract][Full Text] [Related]
13. DKK1 in multiple myeloma.
Hofbauer LC; Neubauer A; Schoppet M
N Engl J Med; 2004 Apr; 350(14):1464-6; author reply 1464-6. PubMed ID: 15074002
[No Abstract] [Full Text] [Related]
14. DKK1 in multiple myeloma.
Lu CM
N Engl J Med; 2004 Apr; 350(14):1464-6; author reply 1464-6. PubMed ID: 15074001
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
